Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Massachusetts 02114, USA.
Am J Hematol. 2012 May;87 Suppl 1:S108-12. doi: 10.1002/ajh.23186. Epub 2012 Apr 4.
Testing for hereditary thrombophilia typically includes tests for activated protein C resistance (APC-R) and/or factor V Leiden, protein C, protein S, antithrombin, and prothrombin G20210A. New options for these assays have become available in recent years, with different advantages and disadvantages among the currently available methods. Potential interferences for each assay type are discussed, including lupus anticoagulants, heparin, warfarin, direct thrombin inhibitors (such as argatroban, dabigatran, hirudin, or bivalirudin), rivaroxaban, factor deficiencies or elevations, factor V Leiden, and specific mutations that the assay(s) might not be able to detect. Causes of acquired deficiencies are also described, as these must be carefully excluded before diagnosing a hereditary deficiency of protein C, protein S, or antithrombin.
遗传性血栓形成倾向的检测通常包括激活蛋白 C 抵抗(APC-R)和/或因子 V Leiden、蛋白 C、蛋白 S、抗凝血酶和凝血酶原 G20210A 的检测。近年来,这些检测方法有了新的选择,目前可用的方法各有优缺点。讨论了每种检测类型的潜在干扰因素,包括狼疮抗凝物、肝素、华法林、直接凝血酶抑制剂(如阿加曲班、达比加群、水蛭素或比伐卢定)、利伐沙班、因子缺乏或升高、因子 V Leiden 以及检测可能无法检测到的特定突变。还描述了获得性缺乏的原因,因为在诊断蛋白 C、蛋白 S 或抗凝血酶遗传性缺乏之前,必须仔细排除这些原因。